Pancreatic adenocarcinoma: ESMO-ESDO Clinical Practice Guidelines for diagnosis, treatment and follow-up. - Wikidata - wikimedia - TriplyDB

Pancreatic adenocarcinoma: ESMO-ESDO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Pancreatic adenocarcinoma: ESMO-ESDO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

http://www.wikidata.org/entity/Q34301038

about

Road map for pain management in pancreatic cancer: A review Have lessons from past failures brought us closer to the success of immunotherapy in metastatic pancreatic cancer?Is metastatic pancreatic cancer an untargetable malignancy?Perioperative treatment options in resectable pancreatic cancer - how to improve long-term survival Imaging and Therapy of Pancreatic Cancer with Phosphatidylserine-Targeted Nanovesicles Current State of Vascular Resections in Pancreatic Cancer Surgery Immunotherapy for patients with advanced pancreatic carcinoma: A promising treatment Advances in chemotherapy for pancreatic cancer Slug-dependent upregulation of L1CAM is responsible for the increased invasion potential of pancreatic cancer cells following long-term 5-FU treatment Early detection of sporadic pancreatic cancer: strategic map for innovation--a white paper Systematic review of outcomes after distal pancreatectomy with coeliac axis resection for locally advanced pancreatic cancer.Expression status of folate receptor alpha is a predictor of survival in pancreatic ductal adenocarcinoma.Trends in the treatment of resectable pancreatic adenocarcinoma.Molecular mechanisms underlying the role of microRNAs in the chemoresistance of pancreatic cancer.Diabetes, pancreatic cancer, and metformin therapy.Randomised, open-label, phase II study of gemcitabine with and without IMM-101 for advanced pancreatic cancer Prognostic factors and sites of metastasis in unresectable locally advanced pancreatic cancer Diagnostic and Prognostic Impact of Circulating YKL-40, IL-6, and CA 19.9 in Patients with Pancreatic Cancer.Resection of pancreatic ductal adenocarcinoma with synchronous distant metastasis: is it worthwhile?Expression and diagnostic value of HE4 in pancreatic adenocarcinoma.Effect of surgery on pancreatic tumor-dependent lymphocyte asset: modulation of natural killer cell frequency and cytotoxic function The long non-coding RNA HOTTIP promotes progression and gemcitabine resistance by regulating HOXA13 in pancreatic cancer.Elastography in pancreatic solid tumours diagnoses.Sequential FOLFIRI.3 + Gemcitabine Improves Health-Related Quality of Life Deterioration-Free Survival of Patients with Metastatic Pancreatic Adenocarcinoma: A Randomized Phase II Trial.Hepatoid carcinoma of the pancreas.Meta-analysis of benefits of portal-superior mesenteric vein resection in pancreatic resection for ductal adenocarcinoma.Gemcitabine Plus Cisplatin for Advanced Biliary Tract Cancer: A Systematic Review Integrating patient reported measures as predictive parameters into decisionmaking about palliative chemotherapy: a pilot study.Clinical impact of neoadjuvant treatment in resectable pancreatic cancer: a systematic review and meta-analysis protocol.Quality appraisal of clinical practice guidelines on pancreatic cancer: a PRISMA-compliant article.Health services research of integrative oncology in palliative care of patients with advanced pancreatic cancer.Complete pathological response following neoadjuvant FOLFIRINOX in borderline resectable pancreatic cancer - a case report and review Diagnostic Value and Interreader Agreement of the Pancreaticolienal Gap in Pancreatic Cancer on MDCT.Multimodality treatment of recurrent pancreatic cancer: Mith or reality?Improving Survival of Pancreatic Cancer. What Have We Learnt?Early vs. Late Chemoradiation Therapy and the Postoperative Interval to Adjuvant Therapy Do Not Correspond to Local Recurrence in Resected Pancreatic Cancer.Patient and caregiver awareness of pancreatic cancer treatments and clinical trials.A phase 3 randomized, double-blind, placebo-controlled trial of ganitumab or placebo in combination with gemcitabine as first-line therapy for metastatic adenocarcinoma of the pancreas: the GAMMA trial.Overuse of surgery in patients with pancreatic cancer. A nationwide analysis in Italy Identification of Poor-outcome Biliopancreatic Carcinoma Patients With Two-marker Signature Based on ATF6α and p-p38 "STARD Compliant".

P2860

Q26738297-3C88A405-05AD-4BB4-8182-C03E05870DC0 Q26747695-F0EC4957-65C0-4516-954B-77C067664B1D Q26753849-97F8B22D-F47F-4631-B30B-74C0DFD270D5 Q26753854-F19F863E-3BB7-4AD4-83E1-27509D96EBCA Q26828959-E05F45ED-51D3-4226-919D-B386B3DC798B Q26861676-EC3D744E-690E-45BB-B383-A4241B52E1C4 Q28074428-9FF1DD68-32EC-455F-AE13-AAF8388B2B3E Q28085711-4A5D937C-0F10-4CC5-A9E6-01AF9620744D Q28546067-0B863F39-8401-4B96-8009-22E7FDD37CE5 Q28648456-4ABC3970-2A74-4438-8B89-039C7E2C5158 Q30249609-35BDEB2B-7B63-48D2-BED2-05FBBB418F74 Q33914066-F1962FFD-CD5D-4CA0-8EB8-188D8FDF5E7A Q34062486-C5F228E9-8A5A-4E3E-BFEE-7BC4A6A67324 Q34177065-AD93C845-5B39-44EA-885F-FC4C4B520647 Q34471173-0125D802-1C2F-4C8A-BA9E-84523645516D Q34539541-8990DFA7-8EFB-4983-9D69-99E88D5A0F5D Q34669394-A80B5DBF-8029-429F-A0BF-2E58DFE98425 Q34806348-395CB82B-E3E1-423A-A1D2-067B3F087187 Q34896040-F6C4897B-45C5-4F98-8549-1B81BFFE8CDE Q35138972-0B19595D-EF7F-4F1F-B7B0-6A86F3FE04F8 Q35174270-FABFE097-71AE-40C4-ABD7-2B0AA4E1003C Q35212896-43DB2951-F4D3-4814-830C-3E3EC4B25842 Q35543615-643CA8CA-DAF9-4093-97A4-6AAED7D918C6 Q35641643-185FB072-6060-4B34-9900-B46B510CAD13 Q35645600-7A915E66-8BB1-4B96-9142-3AA28AA8BDF6 Q35867892-AE80134E-777E-4081-A6A1-5A0ED7D02D30 Q35871195-2D2C9883-476E-4418-99E2-15AF97900F6C Q35940367-789514D9-55D7-4027-8150-74115B0EB1DB Q35970766-779C3601-1386-422F-A097-9EFD7B73EA78 Q36009104-4DEA5B8B-35E4-4705-8AD6-90604305F5FE Q36093374-5ED6DEF3-7200-4940-9AED-1DE3FE45B4D7 Q36159880-B2EA29B1-12FA-48B5-9C57-AF3A6DEF3AB1 Q36205503-C836F9AB-CBBF-4C68-8976-B440515D990C Q36369834-FA844595-7C7E-4159-A409-7706B739236A Q36400047-0DFB2CFD-3988-4421-A3FC-C5D43FFA719F Q36462847-441C50F0-A5FE-42A9-867D-6F4847D84482 Q36666602-11C451B0-DE16-42B7-B289-EF747FFB8910 Q36719024-DA9BE3B1-2BF7-4899-BD27-5DB4462DA9E0 Q36870686-FDE5E7D3-B7DE-49E1-BE22-FE8BCB0CBA57 Q37016687-25508EA2-89F9-4C18-856D-924C51911359

P2860

Pancreatic adenocarcinoma: ESMO-ESDO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

http://www.wikidata.org/entity/Q34301038

description

2012 nî lūn-bûn

@nan

2012 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Pancreatic adenocarcinoma: ESM ...... osis, treatment and follow-up.

@ast

Pancreatic adenocarcinoma: ESM ...... osis, treatment and follow-up.

@en

Pancreatic adenocarcinoma: ESM ...... osis, treatment and follow-up.

@nl

type

label

Pancreatic adenocarcinoma: ESM ...... osis, treatment and follow-up.

@ast

Pancreatic adenocarcinoma: ESM ...... osis, treatment and follow-up.

@en

Pancreatic adenocarcinoma: ESM ...... osis, treatment and follow-up.

@nl

prefLabel

Pancreatic adenocarcinoma: ESM ...... osis, treatment and follow-up.

@ast

Pancreatic adenocarcinoma: ESM ...... osis, treatment and follow-up.

@en

Pancreatic adenocarcinoma: ESM ...... osis, treatment and follow-up.

@nl

P1433

Q34301038-57E75409-DA8C-4194-81E8-63362851CD9E

P1476

Q34301038-FDC84FB7-C14D-4D87-A306-D8D85564A287

P2093

Q34301038-2C6A2770-5EA5-4722-ADCC-9AF009F59D7C

Q34301038-51F74E05-7D39-452A-82B8-CD0383BFF3E1

Q34301038-76500874-82FB-49BC-946F-2C05A5AA5970

Q34301038-B5332DDA-51E9-4FE9-9FA3-77B2CB20BE28

Q34301038-CF7EFA4F-09C1-4FCF-804C-2827D414A7BB

P2860

Q34301038-0BB00A48-531B-46DA-AE7A-6B56B26C031D

Q34301038-0D3D4A06-8E5E-4161-AB09-A189439ACBFA

Q34301038-1E3E7E4E-0E36-4353-883E-9086036F731E

Q34301038-2ABA1B42-94BB-455B-A88E-F28DF503A4CB

Q34301038-3363F992-8692-4E1C-BF74-73E792E5BB54

Q34301038-3CA8B38C-2A24-4B49-B578-AB2008D00B0A

Q34301038-4C1D5D8F-A752-4B9F-81BD-7A8C97725DCB

Q34301038-52902784-596D-45A4-8F9F-9A8FBF569F6A

Q34301038-6A560269-5264-46CE-9570-44070BC59581

Q34301038-767BF7A8-91F0-46EF-AA6C-878776E7F0F7

P304

Q34301038-4720A13A-6D23-4606-AD9C-5F412F997828

P31

Q34301038-E59266D4-5096-43C4-B4F0-2A512D1D13BE

P356

Q34301038-A429A471-F20A-453E-97F7-31F5AAB3BF19

P478

Q34301038-3310580D-6613-4687-AA9A-5764B2CF8A2B

P577

Q34301038-CBAE493A-AD46-453B-8D69-FE6001543079

P5875

Q34301038-5D54D3E9-10B4-45C6-BA62-613D07DB5DDC

P698

Q34301038-5FF75319-C6D0-4BDF-B603-13CCF0407E7A

P921

Q34301038-65CBACEA-9731-4A20-805E-E5F9445B974C

P356

P1433

Annals of Oncology

P1476

Pancreatic adenocarcinoma: ESM ...... osis, treatment and follow-up.

@en

P2093

E Van Cutsem

http://www.w3.org/2001/XMLSchema#string

ESMO Guidelines Working Group

http://www.w3.org/2001/XMLSchema#string

J B Bachet

http://www.w3.org/2001/XMLSchema#string

P Rougier

http://www.w3.org/2001/XMLSchema#string

T Seufferlein

http://www.w3.org/2001/XMLSchema#string

P2860

Global cancer statistics

Red and processed meat consumption and risk of pancreatic cancer: meta-analysis of prospective studies

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial

FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer

Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group

Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer.

Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology Group.

Parenteral nutrition support for patients with pancreatic cancer. Results of a phase II study

Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial.

Body mass index and risk, age of onset, and survival in patients with pancreatic cancer

P304

vii33-40

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/ANNONC/MDS224

http://www.w3.org/2001/XMLSchema#string

P478

23 Suppl 7

http://www.w3.org/2001/XMLSchema#string

P577

2012-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

273734574

http://www.w3.org/2001/XMLSchema#string

P698

22997452

http://www.w3.org/2001/XMLSchema#string

P921